ワクチン技術の世界市場

世界のワクチン技術の市場規模は、2023年の450億米ドルから、予測期間中は7.8%のCAGRで推移し、2028年末には653億米ドルの規模に成長すると予測されています。

サブユニット、遺伝子組換え、多糖類、結合型ワクチンの部門は、2023年の235億米ドルから、同期間中7.9%のCAGRで推移し、2028年には344億米ドルの規模に成長すると予測されています。また、弱毒化ワクチンの部門は、2023年の84億米ドルから、7.6%のCAGRで推移し、2028年には121億米ドルの規模に成長すると予測されています。

当レポートでは、世界のワクチン技術の市場を調査し、市場および技術の背景、市場影響因子の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術動向、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

• 市場の見通し
• 市場洞察

第3章 市場および技術の背景

• 定義
• 免疫システムとワクチン
• 免疫システムのコンポーネント
• 免疫システムの細胞
• 免疫反応
• 主要組織適合性複合体 (MHC)
• 予防接種とワクチン
• 免疫システムの障害
• ライフスタイルが免疫システムに及ぼす影響
• ワクチンの仕組み
• 予防接種の原則
• 免疫の種類
• ワクチン接種の利点
• ワクチンの歴史
• ワクチンと予防接種、概要
• ワクチンの種類
• 弱毒化 (生) ワクチン
• 不活化 (死滅) ワクチン
• トキソイドワクチン
• サブユニットワクチン
• 結合型ワクチン
• 組換えベクターワクチン
• DNAワクチン
• RNAワクチン
• 免疫
• 予防接種の利点
• アジュバントおよび賦形剤
• 病原体の成分
• 粒子状アジュバント
• ワクチンで予防できる感染症
• 人間の病気
• ウイルス性疾患
• 細菌性疾患
• 規制の側面
• 世界保健機関 (WHO) 認定済みワクチン
• 新製品の承認
• リコール
• ワクチンにおける重要な規制の進展

第4章 市場力学

• 概要
• 市場促進要因
• 予防接種に対する意識の高まり
• 投資と研究開発の拡大
• 新しいワクチン
• 感染症の流行
• 市場抑制要因
• ワクチンの開発と価格設定
• 市場機会
• 新興市場からの需要の増加
• 治療用ワクチン

第5章 COVID-19ワクチンの世界市場

• 概要
• COVID-19ワクチン技術
• mRNA技術の登場
• COVID-19による乳児の定期予防接種への影響
• COVID-19による混乱
• 世界のカバー率の停滞
• 国・地域別の進捗と課題

第6章 市場内訳：技術別

• 世界のワクチン技術市場：技術別
• サブユニット、組換え、多糖、複合体ワクチン
• 弱毒化生ワクチン
• 不活化ワクチン
• トキソイドワクチン
• その他/混合ワクチン

第7章 市場内訳：疾患別

• 世界のワクチン技術市場：疾患別
• 肺炎球菌
• ジフテリアと破傷風
• HPV
• MMR
• その他

第8章 市場内訳：年齢層別

• 世界のワクチン技術市場：年齢層別
• 小児
• 青年期・成人

第9章 市場内訳：地域別

• 世界のワクチン技術市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第10章 新たな技術と開発

• 開発状況
• mRNAワクチン
• ウイルスベクターワクチン
• ナノ粒子ワクチン
• DNAワクチン
• ウイルス様粒子 (VLP) ワクチン
• 自己増幅RNAワクチン
• 革新的アジュバント
• AI・計算生物学
• 個別化ワクチン
• 植物ベースワクチン

第11章 競合情勢

• 競合情勢
• 企業シェア分析

第12章 企業プロファイル

• ABBOTT
• ASTRAZENECA
• BAVARIAN NORDIC
• BHARAT BIOTECH INTERNATIONAL LTD.
• EMERGENT BIOSOLUTIONS INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• MITSUBISHI TANABE PHARMA CORP.
• PANACEA BIOTEC LTD.
• PFIZER INC.
• SANOFI

第13章 付録：頭字語のリスト

List of Tables

• Summary Table A : Global Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Summary Table B : Global Market for COVID-19 Vaccines, 2019-2028
• Table 1 : History of Vaccines
• Table 2 : Types of Attenuated (Live) Vaccines
• Table 3 : Pros and Cons of Attenuated (Live) Vaccines
• Table 4 : Types of Inactivated (Killed) Vaccines
• Table 5 : Pros and Cons of Inactivated (Killed) Vaccines
• Table 6 : Types of Toxoid Vaccines
• Table 7 : Pros and Cons of Toxoid Vaccines
• Table 8 : Types of Subunit Vaccines
• Table 9 : Pros and Cons of Subunit Vaccines
• Table 10 : Types of Conjugate Vaccines
• Table 11 : Pros and Cons of Conjugate Vaccines
• Table 12 : Types of Recombinant Vector Vaccines, by Segment
• Table 13 : Pros and Cons of Recombinant Vector Vaccines
• Table 14 : Types of DNA Vaccines, by Segment
• Table 15 : Pros and Cons of DNA Vaccines
• Table 16 : Pros and Cons of RNA Vaccines
• Table 17 : Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines
• Table 18 : Vaccine-Preventable Human Viral Diseases
• Table 19 : Vaccine-Preventable Human Bacterial Diseases
• Table 20 : WHO Prequalified Vaccines, Feb. 2018-April 2020
• Table 21 : Newly Approved Vaccines, Dec. 2018-April 2020
• Table 22 : Emerging Viral Infectious Diseases, 1900-2020
• Table 23 : Global Market for COVID-19 Vaccines, 2019-2028
• Table 24 : WHO-Approved COVID-19 Vaccines: Companies and Technology Adopted
• Table 25 : COVID-19 Vaccines in the Pipeline
• Table 26 : Global Market for Vaccine Technologies, by Vaccine Type , Through 2028
• Table 27 : Global Market for Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, by Region, Through 2028
• Table 28 : Global Market for Live-Attenuated Vaccines, by Region, Through 2028
• Table 29 : Global Market for Inactivated Vaccines, by Region, Through 2028
• Table 30 : Global Market for Toxoid Vaccines, by Region, Through 2028
• Table 31 : Global Market for Other/Combination Vaccines, by Region, Through 2028
• Table 32 : Vaccines, by Disease Type
• Table 33 : Global Market for Vaccine Technologies, by Disease Type, Through 2028
• Table 34 : Global Market for Vaccine Technologies for Pneumococcal Disease, by Region, Through 2028
• Table 35 : Global Market for Vaccine Technologies for Diphtheria and Tetanus, by Region, Through 2028
• Table 36 : Global Market for Vaccine Technologies for HPV, by Region, Through 2028
• Table 37 : Global Market for Vaccine Technologies for MMR, by Region, Through 2028
• Table 38 : Seasonal Influenza Vaccines
• Table 39 : Global Market for Vaccine Technologies for Other Disease Segments, by Region, Through 2028
• Table 40 : Global Market for Vaccine Technologies, by Age Group, Through 2028
• Table 41 : Pediatric Vaccine Doses
• Table 42 : Pediatric/VFC Vaccine Price List, 2019
• Table 43 : Influenza Vaccine Price List, 2020
• Table 44 : Global Market for Vaccine Technologies for Pediatrics, by Region, Through 2028
• Table 45 : Price List of Vaccines for Adolescents and Adults
• Table 46 : Global Market for Vaccines for Adolescents and Adults, by Region, Through 2028
• Table 47 : Global Market for Vaccine Technologies, by Region, Through 2028
• Table 48 : North American Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 49 : North American Market for Vaccine Technologies, by Country, Through 2028
• Table 50 : Immunization Schedule, Canada, 2020
• Table 51 : European Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 52 : European Market for Vaccine Technologies, by Country, Through 2028
• Table 53 : Immunization Schedule, Germany, 2020
• Table 54 : Immunization Schedule, France, 2020
• Table 55 : Vaccination and Immunization Schedule, U.K., 2020
• Table 56 : Immunization Schedule, Italy, 2020
• Table 57 : Asia-Pacific Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 58 : Asia-Pacific Market for Vaccine Technologies, by Country, Through 2028
• Table 59 : Immunization Schedule, China, 2020
• Table 60 : Immunization Schedule, Japan, 2020
• Table 61 : Immunization Schedule, India, 2020
• Table 62 : GAVI Support to India, 2001-2021
• Table 63 : Vaccination Coverage Estimates, Middle East and North Africa, 2014-2020
• Table 64 : Vaccination Coverage, Latin America, and Caribbean, 2014-2020
• Table 65 : RoW Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 66 : RoW Market for Vaccine Technologies, by Sub-Region, Through 2028
• Table 67 : Abbott: Company Snapshot
• Table 68 : Abbott Laboratories: Financial Performance, 2022
• Table 69 : Astrazeneca: Company Snapshot
• Table 70 : AstraZeneca: Vaccines
• Table 71 : AstraZeneca: Recent Developments, 2021
• Table 72 : Bavarian Nordic: Company Snapshot
• Table 73 : Bavarian Nordic: Recent Developments, 2021
• Table 74 : Bharat Biotech: Company Snapshot
• Table 75 : Bharat Biotech: Vaccines
• Table 76 : Bharat Biotech: Recent Developments, 2020 and 2021
• Table 77 : Emergent BioSolutions: Company Snapshot
• Table 78 : Emergent BioSolutions: Vaccines
• Table 79 : Emergent BioSolutions: Recent Developments, 2020 and 2021
• Table 80 : GSK Plc: Company Snapshot
• Table 81 : GSK Plc: Vaccines Offered
• Table 82 : GSK Plc.: Recent Developments, 2020 and 2021
• Table 83 : Johnson & Johnson: Company Snapshot
• Table 84 : Johnson & Johnson: Recent Developments, 2021
• Table 85 : Merck & Co. Inc.: Company Snapshot
• Table 86 : Merck & Co. Inc.: Vaccines
• Table 87 : Merck & Co. Inc.: Recent Developments, 2020 and 2021
• Table 88 : Mitsubishi Tanabe Pharma Corp.: Company Snapshot
• Table 89 : Panacea Biotec Ltd.: Company Snapshot
• Table 90 : Pfizer Inc.: Company Snapshot
• Table 91 : Pfizer Inc.: Recent Developments, 2020 and 2021
• Table 92 : Sanofi: Company Snapshot
• Table 93 : Sanofi: Vaccines
• Table 94 : Sanofi: Recent Developments, 2021
• Table 95 : Acronyms Used in This Report

List of Figures

• Summary Figure A : Global Market for Vaccine Technologies, by Vaccine Type, 2022-2028
• Summary Figure B : Global Market for COVID-19 Vaccines, 2019-2028
• Figure 1 : Global Markets for Vaccine Technologies Market Dynamics
• Figure 2 : Global Market Share of COVID-19 Vaccines, by Technology, 2022
• Figure 3 : Global Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 4 : Global Market for Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, 2020-2028
• Figure 5 : Global Market for Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, by Region, 2020-2028
• Figure 6 : Global Market for Live-Attenuated Vaccines, 2020-2028
• Figure 7 : Global Market for Live-Attenuated Vaccines, by Region, 2020-2028
• Figure 8 : Global Market for Inactivated Vaccines, 2020-2028
• Figure 9 : Global Market for Inactivated Vaccines, by Region, 2020-2028
• Figure 10 : Global Market for Toxoid Vaccines, 2020-2028
• Figure 11 : Global Market for Toxoid Vaccines, by Region, 2020-2028
• Figure 12 : Global Market for Other/Combination Vaccines, 2020-2028
• Figure 13 : Global Market for Other/Combination Vaccines, by Region, 2020-2028
• Figure 14 : Global Market Share of Vaccine Technologies, by Disease Type, 2022
• Figure 15 : Global Market for Vaccine Technologies for Pneumococcal Disease, 2020-2028
• Figure 16 : Global Market for Vaccine Technologies for Pneumococcal Disease, by Region, 2020-2028
• Figure 17 : Global Market for Vaccine Technologies for Diphtheria and Tetanus, 2020-2028
• Figure 18 : Global Market for Vaccine Technologies for Diphtheria and Tetanus, by Region, 2020-2028
• Figure 19 : Global Market for Vaccine Technologies for HPV, 2020-2028
• Figure 20 : Global Market for Vaccine Technologies for HPV, by Region, 2020-2028
• Figure 21 : Global Market for Vaccine Technologies for MMR, 2020-2028
• Figure 22 : Global Market for Vaccine Technologies for MMR, by Region, 2020-2028
• Figure 23 : Global Market for Vaccine Technologies for Other Disease Segments, 2020-2028
• Figure 24 : Global Market for Vaccine Technologies for Other Disease Segments, by Region, 2020-2028
• Figure 25 : Global Market Share of Vaccine Technologies, by Age Group, 2022
• Figure 26 : Global Market for Vaccine Technologies for Pediatrics, 2020-2028
• Figure 27 : Global Market for Vaccine Technologies for Pediatrics, by Region, 2020-2028
• Figure 28 : Global Market for Vaccines for Adolescents and Adults, 2020-2028
• Figure 29 : Global Market for Vaccines for Adolescents and Adults, by Region, 2020-2028
• Figure 30 : Global Market for Vaccine Technologies, by Region, 2020-2028
• Figure 31 : Global Market Share of Vaccine Technologies, by Region, 2022
• Figure 32 : North American Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 33 : North American Market Share for Vaccine Technologies, by Country, 2022
• Figure 34 : U.S. Market for Vaccine Technologies, 2020-2028
• Figure 35 : Canadian Market for Vaccine Technologies, 2020-2028
• Figure 36 : European Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 37 : European Market Share for Vaccine Technologies, by Country, 2022
• Figure 38 : German Market for Vaccine Technologies, 2020-2028
• Figure 39 : Russian Market for Vaccine Technologies, 2020-2028
• Figure 40 : French Market for Vaccine Technologies, 2020-2028
• Figure 41 : U.K. Market for Vaccine Technologies, 2020-2028
• Figure 42 : Italian Market for Vaccine Technologies, 2020-2028
• Figure 43 : Spanish Market for Vaccine Technologies, 2020-2028
• Figure 44 : Rest of the European Market for Vaccine Technologies, 2020-2028
• Figure 45 : Asia-Pacific Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 46 : Asia-Pacific Market Share for Vaccine Technologies, by Country, 2022
• Figure 47 : Chinese Market for Vaccine Technologies, 2020-2028
• Figure 48 : RoW Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 49 : RoW Market Share for Vaccine Technologies, by Sub-Region, 2022
• Figure 50 : Global Market Share for Vaccine Technologies, by Company, 2022
• Figure 51 : Abbott Laboratories: Financial Performance, 2021 and 2022
• Figure 52 : Abbott Laboratories: Revenue Share, by Business Unit, 2022
• Figure 53 : Abbott Laboratories: Revenue Share, by County/Region, 2022
• Figure 54 : AstraZeneca: Net Revenue, 2016-2020
• Figure 55 : AstraZeneca: Revenue Share, by Business Segment, 2020
• Figure 56 : AstraZeneca: Revenue Share, by Region/Country, 2020
• Figure 57 : Bavarian Nordic: Net Revenue, 2016-2020
• Figure 58 : Bavarian Nordic: Revenue Share, by Country, 2020
• Figure 59 : Emergent BioSolutions: Net Revenue, 2016-2020
• Figure 60 : GSK Plc: Net Revenue, 2016-2020
• Figure 61 : GSK Plc: Revenue Share, by Business Segment, 2020
• Figure 62 : GSK Plc: Revenue Share, by Region, 2020
• Figure 63 : Johnson & Johnson: Net Revenue, 2016-2020
• Figure 64 : Johnson & Johnson: Revenue Share, by Business Segment, 2020
• Figure 65 : Johnson & Johnson: Revenue Share, by Country/Region, 2020
• Figure 66 : Merck & Co. Inc.: Net Revenue, 2016-2020
• Figure 67 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
• Figure 68 : Merck & Co. Inc.: Revenue Share, by Region/Country, 2021
• Figure 69 : Panacea Biotec Ltd.: Net Revenue, 2018-2022
• Figure 70 : Panacea Biotec Ltd.: Revenue Share, by Business Segment, 2022
• Figure 71 : Panacea Biotec Ltd.: Revenue Share, by Country/Region, 2022
• Figure 72 : Pfizer Inc.: Net Revenue, 2020-2022
• Figure 73 : Pfizer Inc.: Revenue Share, by Region/Country, 2022
• Figure 74 : Sanofi: Net Revenue, 2017-2021
• Figure 75 : Sanofi: Revenue Share, by Business Segment, 2020
• Figure 76 : Sanofi: Revenue Share, by Region, 2021

Highlights:

The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.

The global market for subunit, recombinant, polysaccharide, and conjugate vaccines is expected to grow from $23.5 billion in 2023 to $34.4 billion by 2028, at a CAGR of 7.9% from 2023 to 2028.

The global market for live-attenuated vaccines is expected to grow from $8.4 billion in 2023 to $12.1 billion by 2028, at a CAGR of 7.6% from 2023 to 2028.

Report Scope:

This report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants.

This report includes only human vaccines; animal vaccines have not been considered in this report.

This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth.

Company mergers, acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type, considering new technologies, growing competition and changing customer needs.

The market has been analyzed based on the application of current vaccines. Categories considered in this report include pneumococcal vaccines; diphtheria, tetanus vaccines; HPV vaccines; MMR vaccines; and other vaccines including rotavirus vaccines, influenza vaccines, hepatitis B vaccines, chickenpox vaccines, polio vaccines, BCG, and yellow fever vaccines.

This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings, and pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest.

This report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this study useful.

Report Includes:

• 34 data tables and 63 additional tables
• An up-to-date overview of the global markets for vaccine technologies
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the market size and revenue forecast for the global market, and a corresponding market share analysis based on technology, disease indication, age group and region
• Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies, global R&D spending, and the regulatory landscape
• Assessment of present and future strategies in the innovation-driven vaccine technologies market, and a look at the vaccines for humans and their immunization schedule
• Discussion of the importance of ESG in the market for vaccine technologies, including consumer attitudes, the impact of ESG factors on company performance, and ESG practices of leading companies
• Review of patents and patent applications
• Overview of the major vendors, along with an analysis of the industry structure, including company market shares, recent M&A activity, and venture funding
• Analysis of the competitive landscape based on recent developments and segmental revenues
• Profiles of the leading companies

Table of Contents

Chapter 1 Introduction

• Study Background
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Insights

Chapter 3 Market and Technology Background

• Definitions
• Immune System and Vaccines
• Components of the Immune System
• Cells of the Immune System
• Immune Response
• Major Histocompatibility Complex (MHC)
• Immunization and Vaccines
• Disorders of the Immune System
• Impact of Lifestyle on the Immune System
• How Vaccines Work
• Principles of Immunization
• Types of Immunity
• Advantages of Vaccination
• History of Vaccines
• Vaccines and Immunization, Overview
• Types of Vaccines
• Attenuated (Live) Vaccines
• Inactivated (Killed) Vaccines
• Toxoid Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• DNA Vaccines
• RNA Vaccines
• Immunization
• Advantages of Immunization
• Adjuvants and Excipients
• Pathogen Components
• Particulate Adjuvants
• Infectious Diseases Preventable by Vaccine
• Human Diseases
• Viral Diseases
• Bacterial Diseases
• Regulatory Aspects
• World Health Organization (WHO) Prequalified Vaccines
• New Product Approvals
• Recalls
• Significant Regulatory Developments in Vaccines

Chapter 4 Market Dynamics

• Overview
• Market Drivers
• Growing Awareness of Immunization
• Growing Investments and R&D
• New Vaccines
• Prevalence of Infectious Diseases
• Market Restraints
• Vaccine Development and Pricing
• Market Opportunities
• Increased Demand from Emerging Markets
• Therapeutic Vaccines

Chapter 5 Global Market for COVID-19 Vaccines

• Overview
• COVID-19 Vaccine Technologies
• Advent of mRNA Technology
• Impact of COVID-19 on Routine Infant Vaccination
• COVID-19 Disruptions
• Stagnating Global Coverage Rate
• Progress and Challenges by Country and Region

Chapter 6 Market Breakdown by Technology

• Global Market for Vaccine Technologies by Technology
• Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Other/Combination Vaccines

Chapter 7 Market Breakdown by Disease

• Global Market for Vaccine Technologies by Disease
• Pneumococcal
• Diphtheria and Tetanus
• HPV
• MMR
• Others

Chapter 8 Market Breakdown by Age Group

• Global Market for Vaccine Technologies by Age Group Treated
• Pediatrics
• Adolescents and Adults

Chapter 9 Market Breakdown by Region

• Global Market for Vaccine Technologies by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 10 Emerging Technologies and Developments

• Developments
• mRNA Vaccines
• Viral Vector Vaccines
• Nanoparticle Vaccines
• DNA Vaccines
• Virus-Like Particle (VLP) Vaccines
• Self-Amplifying RNA Vaccines
• Innovative Adjuvants
• AI and Computational Biology
• Personalized Vaccines
• Plant-Based Vaccines

Chapter 11 Competitive Landscape

• Competitive Landscape
• Company Share Analysis

Chapter 12 Company Profiles

• ABBOTT
• ASTRAZENECA
• BAVARIAN NORDIC
• BHARAT BIOTECH INTERNATIONAL LTD.
• EMERGENT BIOSOLUTIONS INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• MITSUBISHI TANABE PHARMA CORP.
• PANACEA BIOTEC LTD.
• PFIZER INC.
• SANOFI

Chapter 13 Appendix: List of Acronyms

• Acronyms